After the market close, shares of Ziopharm (ZIOP) fell after a regulatory filing from the company was misinterpreted as a new sale of shares. David Connolly, Ziopharm VP of corporate communications and investor relations, noted in a statement that Ziopharm “did not register to sell, the company registered shares as common that were already sold in a private placement.” At their lows, shares traded down to $2.15 per share, but have since come back and are trading at $2.29 per share.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.